Latest News and Press Releases

KNOXVILLE, Tenn., June 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2025 annual stockholder meeting (the...

KNOXVILLE, Tenn., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the launch of VisiRose, Inc. (“VisiRose”),...

KNOXVILLE, Tenn., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that it will host a conference call on Thursday,...

46% complete response of patients at Melanoma Institute AustraliaFifth published study of in-transit melanoma lesion treatment with single-agent PV-1026-50% complete response (52-86% overall response)...

KNOXVILLE, TN, March 30, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent (USP) application...

29% ORR (7% CR) and 57% DCR (RECIST 1.1)75% ORR in anti-PD-1-refractory patients56% DCR (11% CR) in patients refractory to anti-CTLA-4 and anti-PD-1 combination therapyPresentation delivered by...

KNOXVILLE, TN, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center will present non-clinical data from ongoing research on investigational...

Complete response of all injected lesionsRegression of non-injected inguinal node, lung, and brain metastasesExpanded data set of trial subject provided KNOXVILLE, TN, Sept. 21, 2020 (GLOBE...

KNOXVILLE, TN, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Michio Kurosu, PhD, Professor,...

2020 India patent follows 2018 India patent that protects Provectus’ proprietary API manufacturing processProvectus further expands cancer combination therapy IP protection by filing new USPTO patent...